Valuation: Veru Inc.

Market Cap 33.08M 30.13M 27.76M 25.25M 47.37M 3.06B 49.79M 338M 134M 1.67B 124M 121M 5.25B P/E 2026 *
-2x
P/E 2027 * -1.94x
Enterprise Value 33.08M 30.13M 27.76M 25.25M 47.37M 3.06B 49.79M 338M 134M 1.67B 124M 121M 5.25B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.63%
Yield 2026 *
-
Yield 2027 * -
1 day-8.06%
1 week-7.18%
Current month-11.42%
1 month-18.49%
3 months-24.81%
6 months-10.60%
Current year-9.35%
1 week 1.93
Extreme 1.93
2.34
1 month 1.93
Extreme 1.93
2.37
Current year 1.93
Extreme 1.93
7.33
1 year 1.93
Extreme 1.93
7.33
3 years 1.93
Extreme 1.93
19.2
5 years 1.93
Extreme 1.93
245.5
10 years 1.93
Extreme 1.93
245.7
Manager TitleAgeSince
Chief Executive Officer 65 31/10/2016
Director of Finance/CFO 67 01/01/2013
Chief Tech/Sci/R&D Officer 64 01/04/2018
Director TitleAgeSince
Chairman 65 01/03/2018
Director/Board Member 68 01/10/2016
Director/Board Member 68 01/03/2018
Date Insider Type Main position Quantity % Market Cap. Importance
8/13/26 A Buy

Chief Technology Officer

1,800 0.0112%
5/4/26 A Free

Director

160,000 0.9969%
5/4/26 A Free

Director

102,000 0.6355%
Change 5-day change 1-year change 3-year change Capi.($)
-8.06%-7.18%-13.00%-80.34% 33.08M
-2.49%-3.76%+50.31%+62.10% 63.66B
-0.63%-2.91%+6.20%+89.22% 58.56B
-2.37%-2.22%+22.87%+82.31% 54.19B
-2.19%-6.15%+11.92%+108.08% 44.66B
-1.89%-7.28%+13.22%+19.74% 40.51B
-0.93%-0.47%+19.73%+43.75% 36.27B
+1.11%-6.44%+130.68%+641.83% 34.89B
-0.80%+0.61%+77.26%+56.26% 32.26B
-2.17%+16.65%-29.21%+474.05% 31.01B
Average -2.04%-1.81%+29.00%+149.70% 40B
Weighted average by Cap. -1.48%-1.85%+32.16%+150.88%

Financials

2026 *2027 *
Net sales - -
Net income -23.1M -21.04M -19.39M -17.64M -33.08M -2.14B -34.77M -236M -93.78M -1.17B -86.67M -84.85M -3.67B -35.15M -32.02M -29.5M -26.84M -50.35M -3.26B -52.91M -359M -143M -1.78B -132M -129M -5.58B
Net Debt - -
Projected Income Statement - Annual - Veru Inc.
Logo Veru Inc.
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Employees
20
Date Price Change Volume
20/11/26 $1.940 -8.06% 247,921
19/11/26 $2.110 -8.66% 77,038
18/11/26 $2.310 +7.94% 467,374
17/11/26 $2.140 +2.88% 305,004
16/11/26 $2.080 -0.48% 198,904
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Veru Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.940USD
Average target price
25.67USD
Spread / Average Target
+1,223.02%
  1. Stock Market
  2. Stocks
  3. VERU Stock